• Home
  • News
  • Coins2Day 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthOpiod Epidemic

Justice Department Charges 601 Defendants for Health Care Fraud and Opioid Epidemic-Related Schemes

By
Sarah Gray
Sarah Gray
Down Arrow Button Icon
By
Sarah Gray
Sarah Gray
Down Arrow Button Icon
June 29, 2018, 6:02 PM ET

The federal government is cracking down on healthcare schemes — including fraud it says is contributing to the opioid epidemic.

The Department of Justice and the Department of Health and Human Services announced charges against 601 defendants on Thursday, in a massive action taken against health care fraud.

The DOJ alleges that there was more than $2 billion in fraud perpetrated by health care professionals (including doctors and nurses), pharmacies and others. And while the focus was on billing scams to defraud Medicaid, Medicare, Tricare and private insurance companies — by submitting claims for things like medically unnecessary treatment, or treatments that were never provided to the patient — opioid schemes were also targeted.

Of the 601 defendants charged, 162 of them — including 76 doctors — were levied charges related to prescribing or distributing opioids or other narcotics.

In 2016, opioids contributed to 42,249 U.S. Deaths and made up 66% of all overdose deaths.

Among the long list of charges on the DOJ’s website are two medical professionals in the Northern District of Iowa charged with opioid-related schemes, a Delaware physician who owned a pain management clinic charged with “unlawfully prescribing more than two million dosage units of oxycodone products,” and a pharmacy chain owner along with two others in Texas who were charged with using “fraudulent prescriptions to fill bulk orders for over one million pills of hydrocodone and oxycodone, which the pharmacy, in turn, sold to drug couriers for millions of dollars.”

Not included in this particular action by the DOJ and HHS are any major pharmaceutical companies, which have been blamed for contributing to the opioid crisis. The DOJ has not responded to Coins2Day’s request for comment on this.

In May, attorneys general from six states filed lawsuits against Purdue Pharma, the maker of opioid painkiller OxyContin, alleging among other charges that the company misrepresented or failed “to adequately disclose the risk of addiction of opioids.”

Purdue Pharma has been blamed for planting “the seeds of the opioid epidemic,” as one writer for the New York Times put it in a May piece about a confidential DOJ report that alleges Purdue knew about abuse of OxyContin.

“Suggesting that activities that last occurred more than 16 years ago are responsible for today’s complex and multifaceted opioid crisis is deeply flawed,” Purdue spokesman Robert Josephson said in a statement to the Times.

Purdue was the first company to make slow-release pain killers, which it aggressively marketed to physicians based on a phrase on the label not backed up by clinical trials, according to Marketplace’s The Uncertain Hour.

“We share public officials’ concerns about the opioid crisis, and while our opioid medicines account for less than two-percent of total prescriptions, we are committed to working collaboratively toward meaningful solutions to address this public health challenge,” Josephson said in a statement to Coins2Day, which continued:

We vigorously deny these allegations and look forward to the opportunity to present our substantial defenses. The majority of the states claim that Purdue acted improperly by communicating with prescribers about scientific and medical information that FDA has expressly considered and continues to approve. We believe it is inappropriate for these states to substitute their judgment for the judgment of the regulatory, scientific and medical experts at FDA.

Purdue ended its sales representative promotion of opioids in February.

In the past, at least 16 states have filed lawsuits against pharmaceutical companies for their alleged role in the opioid epidemic.

About the Author
By Sarah Gray
See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Coins2Day 500
  • Global 500
  • Coins2Day 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Coins2Day Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Coins2Day Brand Studio
  • Coins2Day Analytics
  • Coins2Day Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Coins2Day
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Coins2Day Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Coins2Day Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.